We recently published a list of Jim Cramer Stock Portfolio for Q4: Top 11 Stocks to Buy and Sell. Since Zoetis Inc (NYSE:ZTS) ranks 4th on the list, it deserves a deeper look.

Jim Cramer in a latest program on CNBC talked about the importance of using short-term rallies to your advantage. He said that investors should know when to take the chips off the table.

“The idea that you should buy and hold through both the best of times and worst of times is probably incredibly foolish, with only very few exceptions,” Cramer said.

Cramer said that if the stock you bought is going higher and higher and you keep resisting the urge to take some profits, you won’t make any actual money from these gains if the stock comes down later paring all these profits. This seems straightforward but the idea of buying low and selling high is easier said than done, Cramer said.

“Don’t get carried away by the optimism. Instead, keep your head on straight, check your emotions, focus on long term and think about ringing the register, especially on stocks that might be getting too high,” Cramer added.

For this article we watched several latest programs of Jim Cramer aired on CNBC and picked 10 stocks he’s talking about. We also picked an interesting prediction Cramer made back in 2021 about a stock and saw how it turned out. With each company we have mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Budimir Jevtic/Shutterstock.com

Zoetis Inc (NYSE:ZTS)

Number of Hedge Fund Investors: 61

When asked about Zoetis Inc (NYSE:ZTS), Jim Cramer said he likes the stock “very much.”

Cramer said CNBC recently had CEO Kristin Peck on and the executive is doing a “great job.”

Zoetis Inc (NYSE:ZTS) makes vaccines and medicines for pets and livestock.

Barclays recently published a list of recession-resilient stocks. Zoetis was part of the list.

The firm’s analyst Anshul Gupta said these stocks have daily average option notional volumes of more than $5M and have strong upside.

Investors are watching Zoetis Inc (NYSE:ZTS) because of Librela, its new medication for treating osteoarthritis (OA) in dogs, a chronic joint condition with no cure.

The U.S. Food and Drug Administration (FDA) approved Librela in May 2023, and it was cleared for use in Europe in 2020. According to the company’s Q2 report, Librela and Solensia, a similar medication for cats, generated $116 million and $150 million in sales combined.